TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Taiko Pharmaceutical Co., Ltd. ( (JP:4574) ) has provided an update.
Taiko Pharmaceutical Co., Ltd. reported a decline in its financial performance for the first nine months of 2025, with net sales decreasing by 7.6% and operating profit dropping by 55.3% compared to the previous year. Despite the challenging financial results, the company’s equity-to-asset ratio improved to 69.3%, indicating a stronger financial position. The company has revised its earnings forecasts for the full fiscal year, anticipating minimal growth in net sales and significant declines in operating and ordinary profits, which may impact its market positioning and stakeholder confidence.
More about Taiko Pharmaceutical Co., Ltd.
Taiko Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, primarily focusing on the production and distribution of healthcare products. The company is listed on the Tokyo Stock Exchange and is known for its products, including Seirogan, which is a popular gastrointestinal medication in Japan.
Average Trading Volume: 214,415
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen13.82B
For a thorough assessment of 4574 stock, go to TipRanks’ Stock Analysis page.